Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<div><ul><li style="list-style-type: square;">Clinical programs. Anixa has two key therapeutic programs: (1) a novel CAR-T cell therapy for terminally ill ovarian cancer patients; and (2) a breast cancer vaccine.</li><li style="list-style-type: square;">The CAR-T program targets resistant and recurrent ovarian cancer, while the breast cancer vaccine aims to treat current breast cancer, prevent recurrence in survivors, and ultimately offer primary prevention.</li><li style="list-style-type: square;">Strategic partnerships with institutions like Cleveland Clinic and Moffitt Cancer Center have helped keep trial costs in check, enabling Anixa to maintain an incredibly low annual cash burn rate of about $5-7MM.</li></ul></div>

Clinical programs. Anixa has two key therapeutic programs: (1) a novel CAR-T cell therapy for terminally ill ovarian cancer patients; and (2) a breast cancer vaccine.The CAR-T program targets resistant and recurrent ovarian cancer, while the breast cancer vaccine aims to treat current breast cancer, prevent recurrence in survivors, and ultimately offer primary prevention.Strategic partnerships with institutions like Cleveland Clinic and Moffitt Cancer Center have helped keep trial costs in check, enabling Anixa to maintain an incredibly low annual cash burn rate of about $5-7MM.

ANIX: Clinical Progress, Partnerships, and Financial Discipline

Anixa Biosciences Inc

ANIX: Clinical Progress, Partnerships, and Financial Discipline